Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

Abstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response...

Full description

Bibliographic Details
Main Authors: Hong Wei, Hanyu Jiang, Bin Song
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.2464
id doaj-9b4d1df525ef4d32b9e0898b2663f615
record_format Article
spelling doaj-9b4d1df525ef4d32b9e0898b2663f6152020-11-25T01:30:09ZengWileyCancer Medicine2045-76342019-09-018125399541310.1002/cam4.2464Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis predictionHong Wei0Hanyu Jiang1Bin Song2Department of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaDepartment of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaDepartment of Radiology Sichuan University West China Hospital Chengdu Sichuan Province ChinaAbstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review.https://doi.org/10.1002/cam4.2464biomarkercancerimagingimmune checkpoint blockaderesponse assessment
collection DOAJ
language English
format Article
sources DOAJ
author Hong Wei
Hanyu Jiang
Bin Song
spellingShingle Hong Wei
Hanyu Jiang
Bin Song
Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
Cancer Medicine
biomarker
cancer
imaging
immune checkpoint blockade
response assessment
author_facet Hong Wei
Hanyu Jiang
Bin Song
author_sort Hong Wei
title Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
title_short Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
title_full Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
title_fullStr Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
title_full_unstemmed Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction
title_sort role of medical imaging for immune checkpoint blockade therapy: from response assessment to prognosis prediction
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2019-09-01
description Abstract Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review.
topic biomarker
cancer
imaging
immune checkpoint blockade
response assessment
url https://doi.org/10.1002/cam4.2464
work_keys_str_mv AT hongwei roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction
AT hanyujiang roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction
AT binsong roleofmedicalimagingforimmunecheckpointblockadetherapyfromresponseassessmenttoprognosisprediction
_version_ 1725093279693799424